Since publication of the positive outcomes of the BANDIT trial in NEJM in December 2023, there has been a lot of interest from the type 1 community about the use of baricitinib for the treatment of type 1 diabetes. The BANDIT team, with support from ATIC’s Community Engagement Panel and Steering Committee, have prepared a position statement to provide guidance and inform decision making for health care professionals considering prescribing off-label baricitnib to treat type 1 diabetes.

The community statement provides a lay summary of the baricitinib position statement. This version provides considerations for members of the type 1 diabetes seeking more information about baricitnib treatment.